Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program

Hepatology

Volumn 61, Issue 6, 2015, Pages 1870-1879

  Lin, Hsi Hsun ^a,b   Lee, Susan Shin Jung ^a,c   Yu, Ming Lung ^d   Chang, Ting Tsung ^e,f   Su, Chien Wei ^a,g   Hu, Bor Shen ^h   Chen, Yaw Sen ^b   Huang, Chun Kai ^b   Lai, Chung Hsu ^b   Lin, Jiun Nong ^b   Wu, Jaw Ching ^a,g  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^g TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^h TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS D VIRUS GENOTYPE IV; UNCLASSIFIED DRUG;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DELTA AGENT HEPATITIS; FEMALE; HEPATITIS B; HEPATITIS B VIRUS GENOTYPE B; HEPATITIS B VIRUS GENOTYPE C; HEPATITIS C; HEPATITIS D VIRUS GENOTYPE II; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; PHYLOGENY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VACCINATION; VIRUS LOAD; AGED; CLINICAL TRIAL; DRUG USE; ENDEMIC DISEASES; GENETICS; HEPATITIS D; HEPATITIS DELTA VIRUS; INCIDENCE; LONGITUDINAL STUDY; MASS IMMUNIZATION; MIDDLE AGED; MIXED INFECTION; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; TAIWAN; VIREMIA; VIROLOGY;

ADULT; AGED; COINFECTION; DRUG USERS; ENDEMIC DISEASES; FEMALE; HEPATITIS B; HEPATITIS B VACCINES; HEPATITIS D; HEPATITIS DELTA VIRUS; HIV INFECTIONS; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MASS VACCINATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; TAIWAN; VIREMIA;

EID: 84929589873     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27742     Document Type: Article

References (39)

1. Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci U S A 1980;77:6124-6128.
2. Wu JC, Chen PJ, Kuo MY, Lee SD, Chen DS, Ting LP. Production of hepatitis delta virus and suppression of helper hepatitis B virus in a human hepatoma cell line. J Virol 1991;65:1099-1104.
3. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009;136:1629-1638.
4. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011;378:73-85.
5. Rizzetto M, Ciancio A. Epidemiology of hepatitis D. Semin Liver Dis 2012;32:211-219.
6. Navascues CA, Rodriguez M, Sotorrio NG, Sala P, Linares A, Suarez A, Rodrigo L. Epidemiology of hepatitis D virus infection: changes in the last 14 years. Am J Gastroenterol 1995;90:1981-1984.
7. Huo TI, Wu JC, Lin RY, Sheng WY, Chang FY, Lee SD. Decreasing hepatitis D virus infection in Taiwan: an analysis of contributory factors. J Gastroenterol Hepatol 1997;12:747-751.
8. Ni YH, Chang MH, Wu JF, Hsu HY, Chen HL, Chen DS. Minimization of HBV infection by a 25-year universal vaccination program. J Hepatol 2012;57:730-735.
9. Huo TI, Wu JC, Wu SI, Chang AL, Lin SK, Pan CH, et al. Changing seroepidemiology of hepatitis B, C, and D virus infections in high-risk populations. J Med Virol 2004;72:41-45.
10. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis D virus genotypes in intravenous drug users in Taiwan: decreasing prevalence and lack of correlation with hepatitis B virus genotypes. J Clin Microbiol 2002;40:3047-3049.
11. Abbas Z, Jafri W, Raza S. Hepatitis D: scenario in the Asia-Pacific region. World J Gastroenterol 2010;16:554-562.
12. Chang SY, Yang CL, Ko WS, Liu WC, Lin CY, Wu CH, et al. Molecular epidemiology of hepatitis D virus infection among injecting drug users with and without human immunodeficiency virus infection in Taiwan. J Clin Microbiol 2011;49:1083-1089.
13. Lee CY, Tsai HC, Lee SS, Wu KS, Sy CL, Chen JK, Chen YS. Higher rate of hepatitis events in patients with human immunodeficiency virus, hepatitis B, and hepatitis D genotype II infection: a cohort study in a medical center in southern Taiwan. J Microbiol Immunol Infect 2015;48:20-27.
14. Chu FY, Chiang SC, Su FH, Chang YY, Cheng SH. Prevalence of human immunodeficiency virus and its association with hepatitis B, C, and D virus infections among incarcerated male substance abusers in Taiwan. J Med Virol 2009;81:973-978.
15. Lu SN, Chen TM, Lee CM, Wang JH, Tung HD, Wu JC. Molecular epidemiological and clinical aspects of hepatitis D virus in a unique triple hepatitis viruses (B, C, D) endemic community in Taiwan. J Med Virol 2003;70:74-80.
16. Hsu HM, Wang YF, Lo SH, Sun HC, Yip KK, Chen JS, et al. Hepatitis D virus infection among intravenous drug abusers in Taiwan: analysis of risk factors and liver function tests. J Med Virol 1990;31:76-81.
17. Liu JY, Lin HH, Liu YC, Lee SS, Chen YL, Hung CC, et al. Extremely high prevalence and genetic diversity of hepatitis C virus infection among HIV-infected injection drug users in Taiwan. Clin Infect Dis 2008;46:1761-1768.
18. Lin HH, Shih YL, Liu YC, Lee SS, Huang CK, Chen YL, et al. An epidemic of HIV type I CRF07_BC infection among injection drug users in Taiwan. J Acquir Immune Defic Syndr 2006;42:248-255.
19. Wu WC, Wu CY, Wang YJ, Hung HH, Yang HI, Kao WY, et al. Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34, 346 subjects. Aliment Pharmacol Ther 2012;36:560-568.
20. Huang YH, Wu JC, Sheng WY, Huo TI, Chang FY, Lee SD. Diagnostic value of anti-hepatitis D virus (HDV) antibodies revisited: a study of total and IgM anti-HDV compared with detection of HDV-RNA by polymerase chain reaction. J Gastroenterol Hepatol 1998;13:57-61.
21. Huang YH, Wu JC, Chang TT, Sheen IJ, Lee PC, Huo TI, et al. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan. J Viral Hepat 2003;10:277-284.
22. Shih HH, Sheen IJ, Su CW, Peng WL, Lin LH, Wu JC. Hepatitis D virus isolates with low replication and epithelial-mesenchymal transition-inducing activity are associated with disease remission. J Virol 2012;86:9044-9054.
23. Shih HH, Jeng KS, Syu WJ, Huang YH, Su CW, Peng WL, et al. Hepatitis B surface antigen levels and sequences of natural hepatitis B virus variants influence the assembly and secretion of hepatitis d virus. J Virol 2008;82:2250-2264.
24. Sy BT, Nguyen HM, Toan NL, Song LH, Tong HV, Wolboldt C, et al. Identification of a natural intergenotypic recombinant hepatitis delta virus genotype 1 and 2 in Vietnamese HBsAg-positive patients. J Viral Hepat 2015;22:55-63.
25. Chu CM, Yeh CT, Liaw YF. Viral superinfection in previously unrecognized chronic carriers of hepatitis B virus with superimposed acute fulminant versus nonfulminant hepatitis. J Clin Microbiol 1999;37:235-237.
26. Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users. J Infect Dis 2010;202:845-852.
27. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996;86:655-661.
28. Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 2009;16:883-894.
29. Gish RG, Yi DH, Kane S, Clark M, Mangahas M, Baqai S, et al. Coinfection with hepatitis B and D: epidemiology, prevalence and disease in patients in Northern California. J Gastroenterol Hepatol 2013;28:1521-1525.
30. Sun CA, Chen HC, Lu SN, Chen CJ, Lu CF, You SL, Lin SH. Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J Med Virol 2001;65:30-34.
31. Popescu GA, Otelea D, Gavriliu LC, Neaga E, Popescu C, Paraschiv S, Fratila M. Epidemiology of hepatitis D in patients infected with hepatitis B virus in bucharest: a cross-sectional study. J Med Virol 2013;85:769-774.
32. Saravanan S, Madhavan V, Velu V, Murugavel KG, Waldrop G, Solomon SS, et al. High prevalence of hepatitis delta virus among patients with chronic hepatitis B virus infection and HIV-1 in an intermediate hepatitis B virus endemic region. J Int Assoc Provid AIDS Care 2014;13:85-90.
33. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet 2000;355:561-565.
34. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, Holmes EC. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 1994;75:1053-1061.
35. Wu JC, Chiang TY, Sheen IJ. Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis. J Gen Virol 1998;79:1105-1113.
36. Su CW, Huang YH, Huo TI, Shih HH, Sheen IJ, Chen SW, et al. Genotypes and viremia of hepatitis B and D viruses are associated with outcomes of chronic hepatitis D patients. Gastroenterology 2006;130:1625-1635.
37. Wu JC, Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet 1995;346:939-941.
38. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol 2013;48:13-21.
39. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int 2010;30:430-437.